Study Finds Repeat Dosing of IVIG and PLEX Common in GBS, Resulting in Harm to Nonresponders

According to randomized controlled trials, repeat intravenous immune globulin (IVIG) dosing and plasma exchange (PLEX) followed by IVIG (combination therapy) have no additional therapeutic benefit in Guillain-Barré syndrome (GBS) nonresponders. Furthermore, the delineation between GBS and acute onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) can be particularly challenging and carries therapeutic implications.

Study Finds Flu Vaccine Over 50% Effective Against Severe Disease in Children

According to a recent study published in JAMA Network Open, the estimated effectiveness of at least one dose of the influenza vaccine against emergency department visits or hospitalization was over 50 percent across disease severity levels among nearly 16,000 U.S. children during five respiratory illness seasons.

New Drug Approved for Children with Severe Immune Disease

Remestemcel-L, a new treatment for children ages 2 months and older with steroid-refractory acute graft-versus-host disease, has been approved by the U.S. Food and Drug Administration.

FDA Approves Celltrion’s Steqeyma to Treat Autoimmune Diseases

Celltrion has received U.S. Food and Drug Administration approval for its autoimmune disease treatment drug Steqeyma, a biosimilar of Johnson & Johnson’s Stelara (ustekinumab).

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

The U.S. Food and Drug Administration (FDA) has granted fast track designation for its lead clinical-stage program, IMM-1-104, as a treatment for patients with unresectable or metastatic NRAS-mutant melanoma who have progressed on or are intolerant to PD-1/PD-L1-based immune checkpoint inhibitors.

New Blood Test for Cancer Patients Makes Treatment Safer and More Effective

Scientists from RMIT University and the Doherty Institute in Australia have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

UNLOXCYT Approved to Treat Metastatic cSCC

Checkpoint Therapeutics’ UNLOXCYT (cosibelimab-ipdl) has been approved by the U.S. Food and Drug Administration to treat adults with metastatic cutaneous squamous cell carcinoma or locally advanced cSCC who are not candidates for curative surgery or curative radiation.

FDA Observes Serious Liver Injury After Treatment with Ocaliva

FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis with Ocaliva who did not have cirrhosis of the liver.

Trial Shows Experimental Cancer Drug Helped Reduce Risk of Death in Common Blood Cancer

Results of a trial of GSK’s experimental cancer drug Blenrep showed that the drug used in combination with other treatments reduced the risk of death by 42 percent in multiple myeloma, at or after first relapse, compared to an existing treatment.

COVID-19 Vaccine May Reduce Risk of Developing Long COVID

A new study published in the journal Vaccine, shows that receiving a COVID-19 vaccine could reduce the risk of developing long COVID if it’s administered five months before an infection.